0.67Open0.67Pre Close0 Volume669 Open Interest270.00Strike Price0.00Turnover2828.46%IV9.91%PremiumJan 17, 2025Expiry Date0.00Intrinsic Value100Multiplier-2DDays to Expiry0.67Extrinsic Value100Contract SizeAmericanOptions Type0.0902Delta0.0099Gamma367.57Leverage Ratio-641.1053Theta0.0000Rho33.14Eff Leverage0.0009Vega
Alnylam Pharmaceuticals Stock Discussion
Alnylam Highlights New Data From HELIOS-B Study of Vutrisiran for the Treatment of Transthyretin Amyloidosis With Cardiomyopathy at Heart Failure Society of America Annual Scientific Meeting 2024 | ALNY Stock News
ALNY BUY ALERT 🚨 DRUG NEWS MULTIPLE PRICE TARGET RAISES
No comment yet